Digital health is entering a more mature phase in 2026 as consolidation accelerates through targeted M&A, driven by the need for scale, artificial intelligence and pressure from payers, investors say.

Included Health is launching an alternative health plan centered on primary care, AI support, price transparency and easier navigation.

Hair loss remains an area lacking biotechnology innovation. The drugs currently available are older products offering limited efficacy. Some of them cannot be used by women. Veradermics aims to shake ...

Three-quarters of the nation’s healthcare providers and payers say they have increased their IT spending over the past year, according to a report released Tuesday by Bain & Company and KLAS Research.

Women’s health has been historically sidelined – underfunded, underresearched and often misunderstood. While interest and investment around complex women’s health have increased, we’re still a long ...

Eli Lilly’s cardiometabolic drug portfolio is expanding with newly approved therapies. To meet demand for those therapies and additional products to come, the company is building a new $2.5 billion ...

As the mental health crisis in the U.S. grows, mental health professionals are increasingly struggling due to workforce shortages. More than half of therapists report having feelings of burnout. And ...

Astellas Pharma is far from alone in viewing cancer as a major growth area, but the Japanese drugmaker has specifically identified a type of therapy called targeted protein degradation as one of the ...

ALung Technologies Inc. has secured $12 million from investors. The Pittsburgh-based medical device company is working toward U.S. regulatory approval of its artificial lung. ALung Technologies Inc.

Epic’s lawsuit against Health Gorilla is less about one alleged data misuse scheme and more about a deeper fault line in healthcare interoperability: data can move faster than the rules governing it.

The first quarter of 2024 saw a significant rise in M&A activity in the hospital and health system space, according to a new report from Kaufman Hall. Experts think that this M&A activity will ...

A rare, inherited endocrine disorder whose standard treatments are steroids that introduce a wide range of side effects now has a new FDA-approved therapy, a non-steroidal Neurocrine Biosciences drug ...